Jefferies initiated coverage on aTyr Pharma with a new price target
$ATYR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Jefferies initiated coverage of aTyr Pharma with a rating of Buy and set a new price target of $9.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/4/2024 | $17.00 | Overweight | Wells Fargo |
| 9/5/2024 | $9.00 | Buy | Jefferies |
SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)
SC 13G - aTYR PHARMA INC (0001339970) (Subject)
SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)
4 - aTYR PHARMA INC (0001339970) (Issuer)
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present two posters related to its tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution, which is scheduled to take place December 8 – 11, 2024, in Whistler, British Columbia, Canada. Details of the presentations appear below. The posters will be available on the aTyr website once presented. Title: A Newly Evolved Domai
Enrollment completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data expected in the third quarter of 2025. Publication in European Respiratory Journal demonstrated statistically significant difference in time-to-first relapse for corticosteroid use and improvement in corticosteroid relapse rate for efzofitimod. SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2024 results and provided a corporate update. "We achieved
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present at several upcoming investor conferences scheduled to take place in November and December 2024. Details of the conferences appear below: Conference: Stifel Healthcare ConferenceDate: Monday, November 18, 2024 Time: 3:35pm ESTLocation: New York, NYFormat: Corporate Presentation Conference: Jefferies London Healthcare Conference Date: Wednesday, November 20, 2024Time: 3:00pm GMTLocation: London, UKFormat: Cor
Wells Fargo initiated coverage of aTyr Pharma with a rating of Overweight and set a new price target of $17.00
Jefferies initiated coverage of aTyr Pharma with a rating of Buy and set a new price target of $9.00
4 - aTYR PHARMA INC (0001339970) (Issuer)
10-Q - aTYR PHARMA INC (0001339970) (Filer)
8-K - aTYR PHARMA INC (0001339970) (Filer)
S-8 - aTYR PHARMA INC (0001339970) (Filer)
The Dow Jones index closed lower by over 500 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Super League Enterprise The Trade: Super League Enterprise, Inc. (NASDAQ:SLE) Director Jeff Patrick Gehl bought a total of 50,000 shares at an average price of $1.35. To acquire these shares, it cost around $67,548. What's Happening: On June
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:ATYR) with a Buy and maintains $35 price target.
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Jayant Aphale, Ph.D., as Vice President, Technical Operations. Dr. Aphale will serve as a member of the Company's executive leadership team, overseeing manufacturing activities at contract development and manufacturing organizations and implementing strategies related to the continuous improvement of commercial manufacturing, supply chain management, process development of new products and product lif